1. Home
  2. KLRS vs TLYS Comparison

KLRS vs TLYS Comparison

Compare KLRS & TLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • TLYS
  • Stock Information
  • Founded
  • KLRS 2019
  • TLYS 1982
  • Country
  • KLRS United States
  • TLYS United States
  • Employees
  • KLRS N/A
  • TLYS N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • TLYS Clothing/Shoe/Accessory Stores
  • Sector
  • KLRS Health Care
  • TLYS Consumer Discretionary
  • Exchange
  • KLRS Nasdaq
  • TLYS Nasdaq
  • Market Cap
  • KLRS 46.0M
  • TLYS 44.0M
  • IPO Year
  • KLRS N/A
  • TLYS 2012
  • Fundamental
  • Price
  • KLRS $3.71
  • TLYS $1.99
  • Analyst Decision
  • KLRS Strong Buy
  • TLYS Hold
  • Analyst Count
  • KLRS 2
  • TLYS 2
  • Target Price
  • KLRS $23.00
  • TLYS $2.25
  • AVG Volume (30 Days)
  • KLRS 689.3K
  • TLYS 236.5K
  • Earning Date
  • KLRS 11-15-2025
  • TLYS 09-03-2025
  • Dividend Yield
  • KLRS N/A
  • TLYS N/A
  • EPS Growth
  • KLRS N/A
  • TLYS N/A
  • EPS
  • KLRS N/A
  • TLYS N/A
  • Revenue
  • KLRS N/A
  • TLYS $549,597,000.00
  • Revenue This Year
  • KLRS N/A
  • TLYS N/A
  • Revenue Next Year
  • KLRS N/A
  • TLYS N/A
  • P/E Ratio
  • KLRS N/A
  • TLYS N/A
  • Revenue Growth
  • KLRS N/A
  • TLYS N/A
  • 52 Week Low
  • KLRS $2.14
  • TLYS $0.57
  • 52 Week High
  • KLRS $24.15
  • TLYS $5.35
  • Technical
  • Relative Strength Index (RSI)
  • KLRS 52.79
  • TLYS 56.80
  • Support Level
  • KLRS $2.37
  • TLYS $1.83
  • Resistance Level
  • KLRS $4.90
  • TLYS $2.08
  • Average True Range (ATR)
  • KLRS 0.70
  • TLYS 0.20
  • MACD
  • KLRS -0.02
  • TLYS -0.00
  • Stochastic Oscillator
  • KLRS 24.95
  • TLYS 33.82

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About TLYS Tilly's Inc.

Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.

Share on Social Networks: